About: Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML).

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on January 2014

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2014 (ast) наукова стаття, опублікована в січні 2014 (uk) مقالة علمية نشرت في يناير 2014 (ar) scientific article published on January 2014 (en)
publication date	wds:Q37490214-79E154FE-3409-4217-9045-580C3FDA29D3
publication date	2014-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37490214-DFCB650F-AC65-43D9-A23C-0EB023443E46
language of work or name	English
cites work	wds:Q37490214-15006617-06DF-4BE4-8DFC-8E33487B1B1A wds:Q37490214-173EEFC2-C800-456C-8169-729C3B0E3DB9 wds:Q37490214-1F58E50F-5579-449B-9ADA-80A4144AE98C wds:Q37490214-2A2B7BE9-EF1A-4B45-90DC-DB45B3CFC222 wds:Q37490214-327529B6-1AB8-46CC-AB4B-9BDCC02C601E wds:Q37490214-73A0BFC8-8170-4DF6-8233-BEDF859CE76E wds:Q37490214-7D3B51E9-BA1B-40C4-8BFE-FF72C12C2555 wds:Q37490214-9AA69198-F452-4C1F-90BC-B75766311B68 wds:Q37490214-A444672B-BD11-44A0-9AB3-A9A4FC0ACB3A wds:Q37490214-A9E3D897-8E1D-4FAD-84E5-845261131FF4 wds:Q37490214-BCFE0C2B-3F78-4E7B-8112-8A375D6AE18B wds:Q37490214-C3EA89CC-5FBE-40CF-B841-10F81C544239 wds:Q37490214-C50FC29C-F4A7-47C2-AF4C-8F31D3AA0B97 wds:Q37490214-C64D61F7-A262-4235-9D27-90E8D177F3C2 wds:Q37490214-C959429B-1FF1-4525-B0D6-8C1C97C5F56F wds:Q37490214-DA7A14F7-45BC-421E-A005-2EFB02B0B2D9 wds:Q37490214-E026FF63-1127-498E-A630-18E063268D4C wds:Q37490214-F6BB7BAA-01B4-490C-AA78-2FCC5366D44D wds:Q37490214-FA03AFBB-D3CB-4627-8DE1-222AC85E4643
cites work	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Harmonization of molecular monitoring of CML therapy in Europe Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib How I treat newly diagnosed chronic phase CML Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. How I treat CML blast crisis Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance Targeted chronic myeloid leukemia therapy: Seeking a cure Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Second-generation BCR-ABL kinase inhibitors in CML. Current treatment strategies in chronic myeloid leukemia. Predicting chronic leukaemias from assessment of complete peripheral blood counts
author name string	wds:Q37490214-F82121BD-61B1-4A9F-8969-12B590929D80
author name string	Ibrahim C Haznedaroglu
rdfs:label	Monitoring the Response to Tyrosine Kinase Inhibitor (nl) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (en) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (ast)
skos:prefLabel	Monitoring the Response to Tyrosine Kinase Inhibitor (nl) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (en) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (ast)
name	Monitoring the Response to Tyrosine Kinase Inhibitor (nl) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (en) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (ast)
title	wds:Q37490214-3F7DB3EE-D830-407E-B0FD-2893453D0A15
title	Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). (en)
page(s)	wds:Q37490214-9ACF9136-3778-4563-B599-2B76566B07CC
page(s)	e2014009
instance of	wds:Q37490214-10A168E3-4CF6-4EF0-B6C0-BE60E7AD0E83
instance of	scholarly article
main subject	wds:Q37490214-93670756-BE42-4FA5-8AE0-4FBA1D452DD1 wds:Q37490214-E4D7A7D2-C057-4E25-99DB-6D978E5773A8
main subject	leukemia chronic myeloid leukemia
PubMed ID	wds:Q37490214-387EC062-706D-4E92-ACD4-B2EE7FD2B35A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24455118
PubMed ID	24455118
published in	wds:Q37490214-B4046C08-1B6E-463F-BE2D-B48BB025D7D5
published in	Mediterranean journal of hematology and infectious diseases
issue	wds:Q37490214-9FF69C3C-B008-49F3-9BDB-067448FAADDA
volume	wds:Q37490214-18DA0DDC-B601-41A3-AB32-296D64F5418E
issue	1
volume	6
DOI	wds:Q37490214-B3BF7B8A-C9EE-4804-903E-5173E077813A
DOI	http://dx.doi.org/10.4084/MJHID.2014.009
DOI	10.4084/MJHID.2014.009
copyright license	wds:Q37490214-e6ea71de-4e45-4a4f-be1f-ff92c5045906
copyright status	wds:Q37490214-a9758608-2f59-475c-a845-1a9de8448ca9
copyright license	Creative Commons Attribution-NonCommercial 4.0 International
copyright status	copyrighted
PMCID	wds:Q37490214-B8219200-28A4-42DA-9AD2-CF796B895C87
PMCID	3894837
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37490214
is cites work of	Novel drug therapies in myeloid leukemia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software